Estrogen Deficiency and the Origin of Obesity during Menopause.

Lizcano F, Guzmán G. · 2014

Read Estrogen Deficiency and the Origin of Obesity during Menopause. by Lizcano F, Guzmán G. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3964739.txt.

Introduction

Fernando Lizcano and Guillermo Guzmán review the link between estrogen loss and weight gain at menopause in BioMed Research International in 2014. Sex hormones shape where fat sits and how fat cells form, and estrogens also tune sugar and fat metabolism through their receptors. Whether losing estrogens at menopause itself drives the metabolic syndrome and heart risk that rise in those years is disputed, and the review takes up that dispute.

The authors trace estrogen action in fat tissue and in the brain centers that govern appetite and energy use. Menopause does bring a clear shift toward abdominal fat and a changed lipid profile. They also weigh estrogen-like compounds from outside the body, including endocrine-disrupting chemicals, as possible players, and they examine how falling estrogen and rising obesity feed each other.

Catalog record

CREATORLizcano F, Guzmán G.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE59 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3964739

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Estrogen Deficiency and the Origin of Obesity during Menopause By Fernando Lizcano, Guillermo Guzmán Published in: BioMed Research International DOI: 10.1155/2014/757461 ABSTRACT Sex hormones strongly influence body fat distribution and adipocyte differentiation. Estrogens and testosterone differentially affect adipocyte physiology, but the importance of estrogens in the development of metabolic diseases during menopause is disputed. Estrogens and estrogen receptors regulate various aspects of glucose and lipid metabolism. Disturbances of this metabolic signal lead to the development of metabolic syndrome and a higher cardiovascular risk in women. The absence of estrogens is a clue factor in the onset of cardiovascular disease during the menopausal period, which is characterized by lipid profile variations and predominant abdominal fat accumulation. However, influence of the absence of these hormones and its relationship to higher obesity in women during menopause are not clear. This systematic review discusses of the role of estrogens and estrogen receptors in adipocyte differentiation, and its control by the central nervous systemn and the possible role of estrogen-like compounds and endocrine disruptors chemicals are discussed. Finally, the interaction between the decrease in estrogen secretion and the prevalence of obesity in menopausal women is examined. We will consider if the absence of estrogens have a significant effect of obesity in menopausal women. 1. INTRODUCTION Obesity and obesity-related disorders such as diabetes mellitus type 2 (DM type 2), cardiovascular disease, and hypertension are worldwide epidemics with a greater percentage of increase in developing countries [1–3]. Many genetic and epigenetic factors determine the pathophysiology of body fat accumulation [4, 5]. The majority of these factors can be classified into different categories [6–9] such as (1) factors responsible for the hormonal regulation of appetite and satiety; (2) factors that regulate body glucose levels [10–12]; (3) regulators of basal metabolic rate [13, 14]; (4) factors that control the quantity, disposition, and distribution of fat cells [15, 16]; (5) modulators for the differentiation of progenitor cells [17, 18]; and (6) those factors that determine adipocyte cell lineage [19, 20]. Adipocytes may also regulate the production of cytokines that control the satiety and hunger centers in the central nervous system and modulate energy expenditure in other tissues [21–23]. The increases in overweight and obesity in menopausal women are important public health concerns [24, 25]. The prevalence of obesity, which is closely associated with cardiovascular risk, increases significantly in American women after they reach age 40; the prevalence reaches 65% between 40 and 59 years and 73.8% in women over age 60 [26]. Unfortunately, there are a limited number of drugs for treatment of obesity, because the majority of new products have been recalled due to side effects [27–29]. The reasons for increasing obesity in menopausal women are not clear. Some researcher arguments that the absence of estrogens may be an important obesity-triggering factor [30]. Estrogens deficiency enhances metabolic dysfunction predisposing to DM type 2, the metabolic syndrome, and cardiovascular diseases [31, 32]. As a result of increases of life expectancy in developed countries, many women will spend the second half of their lives in a state of estrogen deficiency. Thus, the contribution of estrogen deficiency in the pathobiology of multiple chronic diseases in women is emerging as a conceivable therapeutic challenge of the 21st century. However, environmental epigenetic factors may also contribute to obesity and a cultural bias that also hinders women's efforts to combat obesity [33, 34]. Perhaps it is a combination of the aforementioned factors, but the triggers for obesity require further investigation. To address this growing problem, improved understanding of how estrogens contribute to energy balance, lipid, and glucose homeostasis promises to open a novel therapeutic applications for an increasing large segment of the female population. The potential therapeutic relevance of estrogen physiology, estrogen receptors, and the estrogen pathway will be discussed in this manuscript. 2. METHODS The study design was a review of existing published original papers and reviews. We conducted this review of SSBs and health outcomes in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement (PRISMA) [35]. PubMed publications until Nov 30, 2013, were taken into account. 3. ESTROGENS AND ESTROGEN RECEPTORS IN FAT METABOLISM The hormones help integrate metabolic interaction among major organs that are essential for metabolically intensive activities like reproduction and metabolic function. Sex steroids are required to regulate adipocyte metabolism and also influence the sex-specific remodeling of particular adipose depots [36, 37]. In humans, the factors that control fat distribution are partially determined by sex hormones concentrations [38]. Men, on average, have less total body fat but more central/intra-abdominal adipose tissue, whereas women tend to have more total fat that favors gluteal/femoral and subcutaneous depots [39]. Weight and fat abdominal distribution differ among women of reproductive age and menopausal women [40, 41]. The decrease in estrogen levels in menopausal women is associated with the loss of subcutaneous fat and an increase in abdominal fat [42]. The importance of estrogens in subcutaneous fat accumulation is evident; in fact estrogen hormonal therapy in men also increases the amount of subcutaneous fat [43, 44]. In humans, 17-β-estradiol (E2) is the most potent estrogen followed by estrone (E1) and estriol (E3) [45]. The expression of genes that encode the enzymes in estrogen synthetic pathway such as aromatase and reductive 17β-hydroxysteroid dehydrogenases (17β-HSD) is critical for E2 formation [46]. Protein products of several genes with overlapping functions may confer reductive 17β-HSD activities in peripheral tissues [47]. Estrogens function is mediated by nuclear receptors that are transcription factors that belong to the superfamily of nuclear receptors. Two types of estrogen receptors (ERs) have been identified, the alpha (ERα) and beta (ERβ) receptors [48, 49]. The classical genomic action mechanism of ER action typically occurs within hours, leading to activation or repression of target genes. In this classical signaling pathway, ligand activated ER dissociates from its chaperone heat-shock protein and binds as a dimer directly to an estrogen response element (ERE) in the promoter of target genes [50–52], although it was considered that the action of E2 was subject to an action in gene expression regulation. Recently, there is increasing evidence of nonnuclear cytosolic or plasma membrane-associate receptors that mediate nongenomic and rapid effects of several steroid hormones [53–55]. In this manner, the traditional estrogen nuclear receptors have been found to function outside of the nucleus to direct nongenomic effects [56]. Several mechanisms of membrane-signaling activation can explain rapid responses to E2. These rapid actions include activation of kinase, phosphatase, and phospholipase that can mediate calcium-dependent signaling and can mediate downstream nongenomic physiological responses, such as effects on cell cycle, cell survival, and energy metabolism [57, 58]. Human subcutaneous and visceral adipose tissues express both ERα and ERβ [59, 60], whereas only ERα mRNA has been identified in Brown adipose tissue [61, 62]. ERα plays a major role in the activity of adipocytes and sexual dimorphism of fat distribution. Female and male mice that lack ERα have central obesity, have severe insulin resistance, and are diabetic [63–65]. Although not all studies are in agreement, polymorphism of ERα in humans have been associated with risk factors for cardiovascular diseases [66]. Lipolysis in humans is controlled primarily by the action of β-adrenergic receptors (lipolytic) and α2A-adrenergic receptors (antilipolytic) [67]. Estrogen seems to promote and maintain

Read the complete text